Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

FANCC – Prostate Cancer

A targeted sequencing study of 191 men with familial prostate cancer (≥3 affected relatives) assessed 22 DNA repair genes, including FANCC. While 14 putative loss-of-function mutations were identified across the panel, no FANCC variants were observed, indicating no direct genetic link to prostate cancer predisposition in this cohort (PMID:24556621). The absence of FANCC LoF alleles and lack of segregation or prostate cancer–specific functional data support a Limited level of clinical validity for FANCC in prostate cancer. Key take-home: Current evidence does not support FANCC heterozygous mutations as a risk factor for familial prostate cancer.

References

  • British journal of cancer • 2014 • Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. PMID:24556621

Evidence Based Scoring (AI generated)

Gene–Disease Association

Limited

No FANCC loss-of-function variants observed in 191 familial prostate cancer cases ([PMID:24556621]).

Genetic Evidence

Limited

Sequencing of FANCC in 191 familial prostate cancer probands identified no LoF variants ([PMID:24556621]).

Functional Evidence

No Reported Evidence

No functional studies directly assessing FANCC in prostate cancer predisposition.